Found 1027 bookmarks
Newest
Irreversible inhibitors of the proline racemase (PRAC) unveil innovative mechanism of action as antibacterial against Clostridioides difficile
Irreversible inhibitors of the proline racemase (PRAC) unveil innovative mechanism of action as antibacterial against Clostridioides difficile
Proline racemases (PRAC), catalyzing the L-proline and D-proline interconversion, are essential factors in eucaryotic pathogenes such as Trypanosoma cruzi, Trypanosoma vivax and Clostridioides difficile. If the discovery of irreversible inhibitors of Trypanosoma cruzi PRAC (TcPRAC) led to innovative …
·pubmed.ncbi.nlm.nih.gov·
Irreversible inhibitors of the proline racemase (PRAC) unveil innovative mechanism of action as antibacterial against Clostridioides difficile
Researchers attacking menacing 'superbug' -- ScienceDaily - Science Daily
Researchers attacking menacing 'superbug' -- ScienceDaily - Science Daily
Scientists around the world have been working in earnest to improve understanding of an increasingly virulent superbug, Clostridium difficile. The highly contagious hospital-acquired pathogen, designated by the Centers for Disease Control and Prevention as one of the five most urgent threats to the U.S. healthcare system, causes more than 500,000 infections and 29,000 deaths each year at a total societal cost exceeding $5 billion.
·sciencedaily.com·
Researchers attacking menacing 'superbug' -- ScienceDaily - Science Daily
Acurx Announces First Patient Enrolled in Phase 2b Clinical Trial of its Lead Antibiotic for Treatment of Clostridioides difficile Infection (CDI) - BioSpace
Acurx Announces First Patient Enrolled in Phase 2b Clinical Trial of its Lead Antibiotic for Treatment of Clostridioides difficile Infection (CDI) - BioSpace
Acurx Pharmaceuticals, Inc. announced today that the first patient has been enrolled in its Phase 2b clinical trial of ibezapolstat, its lead antibiotic candidate, against the standard of care to treat CDI, vancomycin, in a 64 patient double-blind randomized trial expected to be completed mid-2022.
·biospace.com·
Acurx Announces First Patient Enrolled in Phase 2b Clinical Trial of its Lead Antibiotic for Treatment of Clostridioides difficile Infection (CDI) - BioSpace
Subtractive genomic approach toward introduction of novel immunogenic targets against Clostridioides difficile: Thinking out of the box
Subtractive genomic approach toward introduction of novel immunogenic targets against Clostridioides difficile: Thinking out of the box
Clostridioides difficile is one of the major causes of nosocomial infections worldwide. Antibiotic-associated diarrhea, pseudomembranous colitis, and toxic megacolon are the most common forms of C. difficile infection (CDI). Considering the high antibiotic resistance of C. difficile isolates and the …
·pubmed.ncbi.nlm.nih.gov·
Subtractive genomic approach toward introduction of novel immunogenic targets against Clostridioides difficile: Thinking out of the box
Soluble Non-Starch Polysaccharides From Plantain (Musa x paradisiaca L.) Diminish Epithelial Impact of Clostridioides difficile
Soluble Non-Starch Polysaccharides From Plantain (Musa x paradisiaca L.) Diminish Epithelial Impact of Clostridioides difficile
Clostridioides difficile infection (CDI) is a leading cause of antibiotic-associated diarrhoea. Adhesion of this Gram-positive pathogen to the intestinal epithelium is a crucial step in CDI, with recurrence and relapse of disease dependent on epithelial interaction of its endospores. Close pr …
·pubmed.ncbi.nlm.nih.gov·
Soluble Non-Starch Polysaccharides From Plantain (Musa x paradisiaca L.) Diminish Epithelial Impact of Clostridioides difficile
.@Summitplc’s #ridinilazole reduced recurrence of #Cdiff #infections but did not reach superiority to #vancomycin in Ph3 #ClinicalTrials Believe precision #antibiotic spares #microbiome from damage https://t.co/ED6zpkmEqQ #Cdifficile #InfectiousDiseas
.@Summitplc’s #ridinilazole reduced recurrence of #Cdiff #infections but did not reach superiority to #vancomycin in Ph3 #ClinicalTrials Believe precision #antibiotic spares #microbiome from damage https://t.co/ED6zpkmEqQ #Cdifficile #InfectiousDiseas
.@Summitplc’s #ridinilazole reduced recurrence of #Cdiff #infections but did not reach superiority to #vancomycin in Ph3 #ClinicalTrialsBelieve precision #antibiotic spares #microbiome from damagehttps://t.co/ED6zpkmEqQ#Cdifficile #InfectiousDiseases pic.twitter.com/oUc6TuNkn7— DDNews Online (@DDNewsOnline) December 20, 2021
·twitter.com·
.@Summitplc’s #ridinilazole reduced recurrence of #Cdiff #infections but did not reach superiority to #vancomycin in Ph3 #ClinicalTrials Believe precision #antibiotic spares #microbiome from damage https://t.co/ED6zpkmEqQ #Cdifficile #InfectiousDiseas
The prebiotic effect of human milk oligosaccharides 3'- and 6'-sialyllactose on adhesion and biofilm formation by Clostridioides difficile - pilot study
The prebiotic effect of human milk oligosaccharides 3'- and 6'-sialyllactose on adhesion and biofilm formation by Clostridioides difficile - pilot study
Bacterial adhesion is the first stage of colonisation and biofilm formation by C. difficile. Cell wall proteins (Cwp) 84 and 66 play crucial roles in the pathophysiology of C. difficile and may affect bacterial adhesion. Sialylated human milk oligosaccharides (HMOs) have potential to inhibit bacteri …
·pubmed.ncbi.nlm.nih.gov·
The prebiotic effect of human milk oligosaccharides 3'- and 6'-sialyllactose on adhesion and biofilm formation by Clostridioides difficile - pilot study
Mimicking Native Display of CD0873 on Liposomes Augments Its Potency as an Oral Vaccine against Clostridioides difficile
Mimicking Native Display of CD0873 on Liposomes Augments Its Potency as an Oral Vaccine against Clostridioides difficile
Mucosal vaccination aims to prevent infection mainly by inducing secretory IgA (sIgA) antibody, which neutralises pathogens and enterotoxins by blocking their attachment to epithelial cells. We previously demonstrated that encapsulated protein antigen CD0873 given orally to hamsters induces neutrali …
·pubmed.ncbi.nlm.nih.gov·
Mimicking Native Display of CD0873 on Liposomes Augments Its Potency as an Oral Vaccine against Clostridioides difficile
MIT Advances Toward “Living Biotherapeutics” To Treat Gastrointestinal Diseases - SciTechDaily
MIT Advances Toward “Living Biotherapeutics” To Treat Gastrointestinal Diseases - SciTechDaily
Chemical engineers created a coating for microbes that could make it easier to deploy the organisms to treat gastrointestinal diseases. The human gut is home to thousands of species of bacteria, and some of those bacteria have the potential to treat a variety of gastrointestinal diseases. Some sp
·scitechdaily.com·
MIT Advances Toward “Living Biotherapeutics” To Treat Gastrointestinal Diseases - SciTechDaily
VIDEO: SER-109 may represent 'paradigm shift' in management of recurrent C. difficile - Healio
VIDEO: SER-109 may represent 'paradigm shift' in management of recurrent C. difficile - Healio
Jessica R. Allegretti, MD, MPH, spoke with Healio about a study demonstrating the efficacy of SER-109 in preventing recurrent Clostridioides difficile infection, including in patients using acid-suppressing medications.The data, presented at the ACG Annual Meeting, showed that SER-109 (Seres Therapeutics), an oral investigational microbiome therapeutic, reduced recurrent C. difficile infection
·healio.com·
VIDEO: SER-109 may represent 'paradigm shift' in management of recurrent C. difficile - Healio
VIDEO: CP101 increased microbiome diversity, reduced recurrent C. difficile - Healio
VIDEO: CP101 increased microbiome diversity, reduced recurrent C. difficile - Healio
In this video, Jessica R. Allegretti, MD, MPH, discussed findings from the PRISM3 trial evaluating an investigational therapeutic for the prevention of recurrent Clostridioides difficile infection.Allegretti, director of the fecal microbiota center at Brigham and Women’s Hospital, presented the trial findings at the ACG Annual Meeting.
·healio.com·
VIDEO: CP101 increased microbiome diversity, reduced recurrent C. difficile - Healio
VIDEO: Microbiome therapeutics promising for recurrent C. difficile - Healio
VIDEO: Microbiome therapeutics promising for recurrent C. difficile - Healio
In this video, Jessica R. Allegretti, MD, MPH, discussed a presentation from the ACG Annual Scientific Meeting that provided an overview of microbiome therapeutics  currently under investigation for Clostridioides difficile infection.During his presentation, Sahil Khanna, MBBS, MS, professor of medicine at the Mayo Clinic in Rochester, Minnesota, showed data on RBX2660 (Rebiotix Inc.),
·healio.com·
VIDEO: Microbiome therapeutics promising for recurrent C. difficile - Healio
A step toward 'living biotherapeutics': Chemical engineers have created a coating for microbes that could make it easier to deploy the organisms to treat gastrointestinal disease - Science Daily
A step toward 'living biotherapeutics': Chemical engineers have created a coating for microbes that could make it easier to deploy the organisms to treat gastrointestinal disease - Science Daily
Chemical engineers have developed a protective coating that helps anaerobic microbes survive the manufacturing process, making it potentially easier to use them to treat gastrointestinal disease.
·sciencedaily.com·
A step toward 'living biotherapeutics': Chemical engineers have created a coating for microbes that could make it easier to deploy the organisms to treat gastrointestinal disease - Science Daily
How Microbiome-based Therapeutics May Impact Treatment Landscape for C. Diff Infection, Recurrent C. Diff Infection - Pharmacy Times
How Microbiome-based Therapeutics May Impact Treatment Landscape for C. Diff Infection, Recurrent C. Diff Infection - Pharmacy Times
Teena Chopra, MD, MPH, professor of infectious diseases at Wayne State University, discussed how microbiome-based therapeutics may impact the current treatment landscape for C. diff infection and recurrent C. diff infection.
·pharmacytimes.com·
How Microbiome-based Therapeutics May Impact Treatment Landscape for C. Diff Infection, Recurrent C. Diff Infection - Pharmacy Times
Acurx Pharmaceuticals Earns $12 Price Target From Maxim Group; Ibezapolstat Stays In Focus To Treat C. difficile (NASDAQ: ACXP) - marketscreener.com
Acurx Pharmaceuticals Earns $12 Price Target From Maxim Group; Ibezapolstat Stays In Focus To Treat C. difficile (NASDAQ: ACXP) - marketscreener.com
Acurx Pharmaceuticals Inc. earned a 12-month price target of $12 from analysts at Maxim Group. Coverage was initiated with a BUY rating, and its price target covering the next twelve months. Shares... | December 6, 2021
·marketscreener.com·
Acurx Pharmaceuticals Earns $12 Price Target From Maxim Group; Ibezapolstat Stays In Focus To Treat C. difficile (NASDAQ: ACXP) - marketscreener.com
Finch Therapeutics Announces Positive Topline Results from PRISM-EXT Phase 2 Trial of CP101 for Prevention of Recurrent C. difficile Infection - BioSpace
Finch Therapeutics Announces Positive Topline Results from PRISM-EXT Phase 2 Trial of CP101 for Prevention of Recurrent C. difficile Infection - BioSpace
Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), today announced positive topline results from PRISM-EXT, an open-label extension of the company’s PRISM3 Phase 2 placebo-controlled trial evaluating CP101 for the prevention of recurrent C. difficile infection (CDI).
·biospace.com·
Finch Therapeutics Announces Positive Topline Results from PRISM-EXT Phase 2 Trial of CP101 for Prevention of Recurrent C. difficile Infection - BioSpace
Clostridioides difficile: Innovations in Target Discovery and Potential for Therapeutic Success
Clostridioides difficile: Innovations in Target Discovery and Potential for Therapeutic Success
Considerable progress has been made in the development of new anti-CDI drug candidates. Nevertheless, a greater comprehension of CDI pathogenesis and host-microbe interactions, informed by a systems biology high-throughput interrogation of multidimensional omics and whole structural data, coupled wi …
·pubmed.ncbi.nlm.nih.gov·
Clostridioides difficile: Innovations in Target Discovery and Potential for Therapeutic Success